



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/723,431

11/26/2003

Ning Hu

01992.007US1

6228

53137 7590 05/14/2008
VIKSNINS HARRIS & PADYS PLLP
P.O. BOX 111098
ST. PAUL, MN 55111-1098

EXAMINER

KISHORE, GOLLAMUDI S

ART UNIT

PAPER NUMBER

1612

MAIL DATE

DELIVERY MODE

05/14/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

DETAILED ACTION

The RCE dated 4-28-08 is acknowledged.

Claims included in the prosecution are 1-28, 30-31, 33, 40-42 and 47-71.

Claim Rejections - 35 USC § 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. Claims 1-28, 30-31, 33, 40-42 and 47-71 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 99/13816 in combination with Tardi (US 2003/0124181).

WO 99 discloses a method of loading camptothecins using a pH gradient at a higher temperature, which is same as instant method. The lipids used include DSPC, cholesterol and phosphatidylglycerols. The buffer used is citrate buffer which is more than 5 mM. The lipid to camptothecin ratios are from 5:1 to 100:1 (abstract, pages 10-15, 18, Example 2 and claims). Although in examples, WO uses citric acid at 50 mM concentration, in view of WO's teachings that it can be higher than 5 mM, it would have been obvious to one of ordinary skill in the art to vary the molarity with the expectation of obtaining the best possible results. What is lacking in WO is the loading of active agents other than camptothecins, such as claimed anthracyclines and vinca alkaloids.

Tardi while disclosing liposomal compositions containing various active agents teaches that therapeutic agents which can be loaded using pH gradients comprise one more ionizable moiety such that the neutral form of the ionizable moiety allows the drug to cross the liposome membrane and conversion of the moiety to charged form causes the drug to remain encapsulated within the liposomes. Tardi teaches that the ionizable moieties comprise amine, carboxylic acid and hydroxyl groups. Among the active agents taught by Tardi are camptothecins, vinca alkaloids such as vinblastine, and vincristine and anthracycline antibiotics such as doxorubicin (0080-0081). Tardi further teaches dehydrating the liposomes and the use of cryoprotectants (claims).

The use of the liposomes of WO to load active agents such as anthracycline antibiotics and vinca alkaloids would have been obvious to one of ordinary skill in the art since Tardi teaches that any ionizable active agent having an amine, carboxyl and hydroxyl functional groups can be loaded using pH gradients and those compounds include camptothecins, anthracyclines and vinca alkaloids.

WO does not teach the use of sphingomyelin in the preparation of the liposomes, since it is a commonly used lipid in the liposome formations, it would have been obvious to one of ordinary skill in the art to use this lipid with a reasonable expectation of success.

3. Claims 1-28, 30-31, 33, 40-42 and 47-71 are rejected under 35 U.S.C. 103(a) as being unpatentable over EP 0 719 546.

EP discloses a method of loading active agents using a pH gradient at a higher temperature. The method is applicable to several anti-cancer agents such as doxorubicin, vincristine, purine or pyrimidine compounds, antibiotics and others. The

Art Unit: 1612

lipids used are EPC and cholesterol. Other phospholipids suggested are DSPC, DPPC, DMPC and DAPC. Although in examples, EP teaches the loading of doxorubicin at a higher pH than the interior pH of the liposomes, on col. 20, lines 44-49 it teaches that pH gradients can be established with a second external medium of relatively acidic or basic pH. Therefore, it would have been obvious to one of ordinary skill in the art to load an active agent at an acidic medium and then relative to the liposome interior and then change the pH of the exterior to basic pH such that the active agent remains entrapped. Although EP does not disclose the use of phosphatidylglycerol in the liposomes, since it is the commonly used negatively charged lipid to provide negative charge to the liposomes, it would have been obvious to one of ordinary skill in the art to include this phospholipid with a reasonable expectation of success. One of ordinary skill in the art would be motivated further to include this lipid since WO which is discussed below advocates the use of this lipid in similar active agent loading method.

4. Claims 7 and 49 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 99/13816 in combination with Tardi OR over EP 0 719 546 as set forth above, further in view of Webb (5,814,335) of record.

The teachings of WO, Tardi and EP have been discussed above. What is lacking in these references is the use of sphingomyelin as the liposome-forming lipid. The use of sphingomyelin however, would have been obvious to one of ordinary skill in the art since Webb teaches that sphingomyelin containing liposomes are stable and have extended circulation time (abstract). Neither EP nor WO teaches the change of the pH of the external medium by using methylamine. The use of methylamine to change the

Art Unit: 1612

pH of the external medium would have been obvious to one of ordinary skill in the art with a reasonable expectation of success since Webb teaches the creation of pH gradient using methylamine (columns 7 and 8).

5. Claims 52-57 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 99/13816 in combination with Tardi (US 2003/0124181) OR over EP 0 719 546 as set forth above, further in view of Clerc (5,939,096).

The teachings of Tardi, EP and WO have been discussed above.

Clerc while disclosing a method of drug loading by pH gradient teaches that liposomes can be dehydrated for storage in the presence of cryoprotectant sugars (col. 8, lines 9-15). It would have been obvious to one of ordinary skill in the art to use cryoprotectants and dehydrate liposomes since they can be stored in that state as taught by Clerc.

Double Patenting

6. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to

Art Unit: 1612

be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

7. Claims 1-28, 30-31, 33, 40-42 and 47-71 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-23, 30, 40-42, 47-71 of copending Application No. 10/723,610. Although the conflicting claims are not identical, they are not patentably distinct from each other because claims in both applications are drawn to the same method of loading active agents into liposomes. In instant claims, the acid used has 'at least about 60 mM strength' whereas the acid recited in the copending application has 'up to about 60 mM' strength. First of all the lower limit in instant claims and the upper limit in the claims of copending application overlap since 'about' provides some flexibility. Furthermore, since the active agent is loaded using a pH gradient, it would have been obvious to one of ordinary skill in the art to vary the amounts of the acid to obtain the best possible results. The amended claims in the copending application are drawn to anthracycline chemotherapeutic agents and it would have been obvious to one of ordinary skill in the art to load any compound with a reasonable expectation of success.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

This rejection is maintained since applicant has neither filed a terminal disclaimer nor provided arguments.

Art Unit: 1612

8. Claims 1-28, 30-31, 33, 40-42 and 47-71 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 30-31 and 35-64 of U.S. Patent No. 6,740,335 in combination with Tardi (US 2003/0124181). Although the conflicting claims are not identical, they are not patentably distinct from each other because both patented claims and instant claims are drawn to the process of loading agents using pH gradients. Instant claims are generic with respect to the active agents loaded whereas the patented claims recite specific camptothecin compound. However, it would have been obvious to one of ordinary skill in the art to load any active agent using a pH gradient with a reasonable expectation of success since Tardi teaches that any ionizable active agent having an amine, carboxyl and hydroxyl functional groups can be loaded using pH gradients and those compounds include camptothecins, anthracyclines and vinca alkaloids. Patented claims do not recite the concentration of the acid while loading the active agent and instant mM amounts therefore, are deemed to be anticipated by the claims in the patent.

Applicant's arguments have been fully considered, but are not persuasive, but are deemed to be moot in view of the new rejections.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gollamudi S. Kishore, Ph.D whose telephone number is (571) 272-0598. The examiner can normally be reached on 6:30 AM- 4 PM, alternate Friday off.

Art Unit: 1612

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Krass Frederick can be reached on (571) 272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Gollamudi S Kishore, Ph.D/
Primary Examiner, Art Unit 1612

GSK